Intuitive Surgical reports developments in robotic-assisted minimally invasive care, centered on its da Vinci surgical systems, da Vinci 5, da Vinci SP, and Ion Endoluminal System. Company news commonly covers procedure volume, system placements, installed-base growth, instruments and accessories revenue, operating lease placements, and share repurchase activity.
Updates also include FDA clearances that expand indications for Intuitive platforms, such as cardiac procedures for da Vinci 5 and additional procedures for da Vinci SP. News about the company also reflects completed commercial expansion in Europe, including direct operations for da Vinci and Ion distribution in Southern European markets.
Intuitive (Nasdaq: ISRG) reported strong Q2 2024 financial results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew approximately 17% compared to Q2 2023. The company placed 341 da Vinci surgical systems, including 70 da Vinci 5 systems, bringing the total installed base to 9,203 systems, a 14% increase year-over-year.
GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, while non-GAAP net income was $641 million, or $1.78 per diluted share. Instruments and accessories revenue increased by 16% to $1.24 billion, driven by procedure volume growth. The company ended Q2 with $7.68 billion in cash, cash equivalents, and investments.
Intuitive (NASDAQ: ISRG) announced FDA clearance for revised labeling of its da Vinci X and Xi systems, specific to radical prostatectomy. The revision is based on real-world evidence from 2007 to 2014, indicating similar five- to 10-year cancer survival rates for robotic-assisted and open surgeries. This collaboration involved the FDA, Aetion, and NEST, highlighting the potential of real-world data in regulatory science. The labeling change reflects these findings, affirming the non-inferiority of robotic-assisted surgeries in cancer treatment outcomes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.